Antileishmanial activity of Peganum harmala extract on the in vitro growth of Leishmania major promastigotes in comparison to a trivalent antimony drug

Veterinarski Arhiv

Volumn 77, Issue 4, 2007, Pages 365-375

  Mirzaie, Mohammad ^a   Nosratabadi, Seyyed Jafar ^b   Derakhshanfar, Amin ^a   Sharifi, Iraj ^b  

^a SHAHID BAHONAR UNIVERSITY OF KERMAN   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antileishmanial activity; Leishmania major; MTT assay; Peganum harmala; Potassium antimonyl tartrate

Indexed keywords

LEISHMANIA MAJOR; PEGANUM HARMALA; PHLEBOTOMINAE;

EID: 34548297511     PISSN: 03725480     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. AVLONITIS, N., E. LEKKA, A. DETSI, M. KOUFAKI, T. CALOGEROPOULOU, E. SCOULICA, E. SIAPI, I. KYRIKOU, T. MAVROMOUSTAKOS, A. TSOTINIS, S. G. GRDADOLNIK, A. MAKRIYANNIS (2003): Antileishmanial ring-substituted ether phospholipids. J. Med. Chem. 46, 755-767.
2. BANSAL, D., R. SEHGAL, Y. CHAWLA, R. C. MAHAJAN, N. MALLA (2004): In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar. Ann. Clin. Microbiol. Antimicrob. 3, 27-31.
3. BERMAN, J. D. (1996): Treatment of New World cutaneous and mucosal leishmaniases. Clin. Dermatol. 14, 519-522.
4. BERMAN, J. D. (1997): Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24, 684-703.
5. BOELAERT, M., D. LE-RAY, S. P. VAN-DER (2002): How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis. Trop. Med. Int. Hlth. 7, 955-959.
6. rd ed., CRC Press, New Jersey, pp. 4644-4645.
7. EPHROS, M., E. WALDMAN, D. ZILBERSTEIN (1997): Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob. Agents Chemother. 41, 1064-1068.
8. FAN, B., J. LIANG, J. MEN, F. GAO, G. LI, S. ZHAO, T. HU, P. DANG, L. ZHANG, P. M. PRESTON, H. YIN (1997): Effect of total alkaloid of Peganum harmala L. in the treatment of experimental haemosporidian infections in cattle. Trop. Anim. Hlth. Prod. 29, 77S-83S.
9. GUPTA, N., N. GOYAL, A. K. RASTOGI (2001): In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol. 17, 150-153.
10. HAMBURGER, M., K. HOSTETTMANN (1991): Bioactivity in plants: the link between phytochemistry and medicine. Phytochemistry 30, 3864-3874.
11. HANDMAN, E. (2000): Cell biology of leishmania. Adv. Parasitol. 44, 1-39.
12. HANDMAN, E, (2001): Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14, 229-243.
13. HU, T. J., B. T. FAN, J. LIANG, S. ZHAO, P. DANG, F. GAO, M. X. DONG, P. M. PRESTON, H. YIN (1997): Observations on the treatment of natural haemosporidian infections by total alkaloid of Peganum harmala L. in cattle. Trop. Anim. Hlth. Prod. 29, 72S-76S.
14. HUBER, W., J. C. KOELLA (1993): A comparison of three methods of estimating Ec50 in studies of drug resistance of malaria parasites. Acta Trop. 55, 257-261.
15. KAMEL, S., L. IBRAHIM, A. AFIFI, S. HAMZA (1970): Major alkaloidal constituents of the Egyptian plant. Peganum harmala. UARJ, Vet. Sci. 7, 71-86.
16. LIRA, R., S. SUNDAR, A. MAKHARIA, R. KENNEY, A. GAM, E. SARAIVA, D. SACKS (1999): Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180, 564-567.
17. MAAROUF, M., Y. KOUCHKOVSKY, S. BROWN, P. X. PETIT, M. ROBERT-GERO (1997): In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp. Cell Res. 232, 339-348.
18. MANSKE, R. H. F., H. L. HOLMES (1952): The Alkaloids: Chemistry and Pharmacology, Academic Press. New York Inc. p. 393.
19. MIRZAIEDEHAGHI, M. (2006): Treatment of natural ovine malignant theileriosis with a chloroform extract of the plant Peganum harmala. Onderstepoort J. Vet. Res. 73, 153-155.
20. MOSMANN, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods 65, 55-63.
21. MOTTRAM, J. C., G. H. COOMBS (1985): Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals. Exp. Parasitol. 59, 151-160.
22. NIKS, M., M. OTTO (1990): Towards an optimized MTT assay. J. Immunol. Methods 130, 149-151.
23. ROBERTS, W. L., J. D. BERMAN, P. M. RAINEY (1995): In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob. Agents Chemother. 39, 1234-1239.
24. ROBERTS, W. L., P. M. RAINEY (1993): Antileishmanial activity of sodium stibogluconate fractions. Antimicrob. Agents Chemother. 37, 1842-1846.
25. SERENO, D., J. L. LEMESRE (1997): Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 41, 972-6.
26. VECHERKIN, S. S., A. D. PUZII, V. G. ROMAKHOV, M. P. TRIBUNSKII (1977): The alkaloids of harmel in the treatment of theileriasis. Veterinariya Moscow 10, 77-78.
27. WRIGHT, C. W., J. D. PHILLIPSON (1990): Natural products and the development of selective antiprotozoal drugs. Phytother. Res. 4, 127-39.